arrow
R

Raynell Lang

University of Calgary
H指数:18
被引数:1,153

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Changes in cardiometabolic biomarkers 1 year after direct acting antiviral therapy for hepatitis C virus co‐infection among people with HIV

<scp>HIV</scp>合并丙型肝炎病毒感染者接受直接抗病毒治疗后1年内的心血管代谢生物标志物变化

2026-10-180
OAAI
The effect of hypothetical interventions to limit weight gain on incident type 2 diabetes mellitus among people with HIV initiating antiretroviral therapy in the United States, 2012-2021

2012-2021年,假设干预措施限制体重增加对美国开始抗逆转录病毒治疗的HIV感染者中2型糖尿病发病的影响

2026-10-140
PRE
Changes in HIV Clinical Visit Frequency and Viral Suppression During and After COVID-19 Restrictions: A nested study within NA-ACCORD in the US, 2018–2021

COVID-19限制期间及之后HIV临床就诊频率和病毒抑制的变化:美国NA-ACCORD嵌套研究,2018–2021

2026-09-030
OAAI
Impact of SARS-CoV-2 breakthrough infection on short-term CD4 count among adults with HIV in the United States from 2020-2022

2020-2022年美国HIV感染者中SARS-CoV-2突破性感染对短期CD4计数的影响

2026-05-070
OA
Incident diabetes after switching to integrase strand transfer inhibitors in people with HIV in the USA and Canada: a cohort study

美国和加拿大HIV感染者转换使用整合酶链转移抑制剂后的新发糖尿病:一项队列研究

2026-03-270
PRE
Life-years lost associated with mental disorders in people with HIV: a cohort study in South Africa, Canada and the United States

与精神障碍相关的生命年损失:来自南非、加拿大和美国的一项队列研究

2025-08-180
OAAI
The Real-World Effectiveness of Human Immunodeficiency Virus Pre-Exposure Prophylaxis in Adults in Alberta, Canada: A Retrospective Population-Based Cohort Study

加拿大艾伯塔省成人人类免疫缺陷病毒前暴露预防措施的实际效果:一项基于人群的回顾性队列研究

2025-08-100
OAAI
Changing prevalence and risk factors for Toxoplasma gondii seropositivity and disease in persons with HIV at the Southern Alberta Clinic since 1985

自1985年以来,在南方阿尔伯塔诊所的HIV感染者中,弓形虫(Toxoplasma gondii)血清阳性率和疾病患病率的变化及其危险因素分析。

2025-08-040
PRE
Direct-Acting Antiviral Initiation Among People With Hepatitis C Virus (HCV) and HIV on Antiretroviral Therapy in the United States and Canada: Factors Driving the HCV Treatment Gap

直接抗病毒药物启动治疗在患有丙型肝炎病毒(HCV)和人类免疫缺陷病毒(HIV)且接受抗逆转录病毒治疗的患者中的使用(美国和加拿大):导致HCV治疗差距的因素

2025-08-040
OAAI
Statins for primary prevention of cardiovascular events in people with HIV: target trial and modelling study

他汀类药物用于HIV感染者心血管事件的一级预防:目标试验和建模研究

2025-05-080
OA
Changes in the Prevalence of Non-AIDS Conditions Among Hospitalized Persons With Human Immunodeficiency Virus (HIV) in the United States and Canada, 2008-2018
2025-04-010
PRE
Integrase strand-transfer inhibitor use and cardiovascular events in adults with HIV: an emulation of target trials in the HIV-CAUSAL Collaboration and the Antiretroviral Therapy Cohort Collaboration

整合酶链转移抑制剂的使用和成人HIV患者的心血管事件: HIV因果协作和抗逆转录病毒治疗队列协作中目标试验的模拟

2023-11-019
OAAI
Impact of subgroup-specific heterogeneities and dynamic changes in mortality rates on forecasted population size, deaths, and age distribution of persons receiving antiretroviral treatment in the United States: a computer simulation study

亚组特异性异质性和死亡率动态变化对美国接受抗逆转录病毒治疗者的预测人口规模,死亡和年龄分布的影响: 计算机模拟研究

2023-11-010
OAAI
Hospital Readmissions Among Persons With Human Immunodeficiency Virus in the United States and Canada, 2005-2018: A Collaboration of Cohort Studies
2023-09-122
PRE